Opioid agonist/antagonist has a big impact in phase IIb trial ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Scouted/The Daily Beast/Retailers. Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Clearly, the multifaceted benefits of GLP-1 agonist ...

New weight-loss drugs in the works will offer more choices beyond GLP-1 options Wegovy and Zepbound. What to know about ...

SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient ...

Some people are hitting a weight loss plateau with GLP-1 agonist drugs like Ozempic, so they’re turning to a stronger variety that promises even more dramatic weight loss — up to more than 70 pounds ...

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most effective weight loss medication yet. Retatrutide is a triple-agonist ...

Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides ...

Jan. 14 -- WEDNESDAY, Jan. 13 (HealthDay News) -- Reduced dosages of dopamine agonists, drugs routinely used to treat Parkinson's disease, can cause symptoms similar to those experienced by addicts in ...